Medera
Medera is a clinical-stage biopharmaceutical company focused on eradicating difficult-to-treat and incurable cardiovascular diseases by advancing next-generation gene- and cell-based therapies. It operates through its subsidiaries Novoheart, which specializes in pre-clinical disease modeling and drug discovery using human mini-Heart technology, and Sardocor, which focuses on clinical development of novel cardiovascular gene and cell therapies. The company's mission is to develop innovative therapeutics for unmet medical needs, leveraging proprietary platforms and expedited regulatory pathways.
Industries
Nr. of Employees
medium (51-250)
Medera
6 Tide Street, 2nd Floor, Boston, MA 02210
Products
Engineered human mini-Heart platform (3D ventricular organoid chambers and cardiac tissue strips)
A suite of engineered human cardiac models (ventricular organoid chambers and cardiac tissue strips) that reproduce mechanical and electrical heart function for preclinical toxicity, efficacy and dosing studies.
Automated assay hardware and software for cardiac tissue screening
Automation hardware and accompanying software that increase throughput, accuracy and sensitivity for phenotypic screening using engineered cardiac tissues.
Intracoronary infusion delivery methodology for targeted cardiac therapeutics
A minimally invasive intracoronary infusion procedure designed to deliver gene therapy directly to cardiac ventricular muscle, reducing systemic exposure and required vector dose.
Engineered human mini-Heart platform (3D ventricular organoid chambers and cardiac tissue strips)
A suite of engineered human cardiac models (ventricular organoid chambers and cardiac tissue strips) that reproduce mechanical and electrical heart function for preclinical toxicity, efficacy and dosing studies.
Automated assay hardware and software for cardiac tissue screening
Automation hardware and accompanying software that increase throughput, accuracy and sensitivity for phenotypic screening using engineered cardiac tissues.
Intracoronary infusion delivery methodology for targeted cardiac therapeutics
A minimally invasive intracoronary infusion procedure designed to deliver gene therapy directly to cardiac ventricular muscle, reducing systemic exposure and required vector dose.
Services
Contract research services that provide human-relevant safety, efficacy and dosing data using engineered ventricular organoid chambers, tissue strips, and electrophysiology substrates.
Clinical program development and operational support for AAV-based and cell-based therapies, including IND-enabling activities and conduct of experimental medicine trials.
On-site cGMP manufacturing, process development, technology transfer and analytical support for producing clinical-grade viral vectors (AAV, adenovirus, lentivirus) and stem cell lines.
Contract research services that provide human-relevant safety, efficacy and dosing data using engineered ventricular organoid chambers, tissue strips, and electrophysiology substrates.
Clinical program development and operational support for AAV-based and cell-based therapies, including IND-enabling activities and conduct of experimental medicine trials.
On-site cGMP manufacturing, process development, technology transfer and analytical support for producing clinical-grade viral vectors (AAV, adenovirus, lentivirus) and stem cell lines.
Expertise Areas
- Preclinical cardiac disease modeling
- Cardiac tissue engineering
- iPSC-derived disease modeling
- Phenotypic drug screening
Key Technologies
- 3D engineered human ventricular organoid chambers (hvCOC)
- Induced pluripotent stem cell (iPSC) differentiation to cardiomyocytes
- AAV and other viral vector manufacturing
- Intracoronary infusion delivery